Journal of Pain & Palliative Care Pharmacotherapy最新文献

Editorial: Reasons for Conflicting Evidence Regarding Use of Platelet-Rich Plasma (PRP). 社论：关于使用富血小板血浆 (PRP) 的证据相互矛盾的原因。

IF 0.9

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2024-10-25 DOI: 10.1080/15360288.2024.2406284

Myron Nicholas Senchyshak

引用次数: 0

The Effectiveness of Tramadol in Pain Relief in Chronic Diseases: A Review Based on Clinical Trials. 曲马多缓解慢性病疼痛的疗效：基于临床试验的综述

IF 0.9

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2024-10-23 DOI: 10.1080/15360288.2024.2411239

Kosar Seidmohammadi, Hoda Haghshenas, Sara Moghaddam, Hossein Kargar Jahromi, Hamed Delam

{"title":"The Effectiveness of Tramadol in Pain Relief in Chronic Diseases: A Review Based on Clinical Trials.","authors":"Kosar Seidmohammadi, Hoda Haghshenas, Sara Moghaddam, Hossein Kargar Jahromi, Hamed Delam","doi":"10.1080/15360288.2024.2411239","DOIUrl":"https://doi.org/10.1080/15360288.2024.2411239","url":null,"abstract":"Tramadol is a synthetic opioid with a central effect from the aminocyclohexanol group, which has two main mechanisms of action, including as a weak agonist of opioid receptors and as a norepinephrine and serotonin reuptake inhibitor. The present study presents a review based on clinical trials designed in 2023. In July 2023, six international databases, including Medline/PubMed, ProQuest, Scopus, EMBASE, Google Scholar, and ISI (Web of Science), were searched and 58 articles were included in the study. The results of most studies showed that tramadol can be used as an analgesic drug, although in some studies it was shown that tramadol is not therapeutically superior in reducing pain compared to other treatments. Also, complications related to this treatment have been reported in some studies. Physicians should consider these factors to prevent drug toxicity, poor pain relief, use disorder in patients, and unpredictable complications. It should be noted that there is not enough evidence to support the long-term effectiveness of tramadol, but this argument also extends to nonopioid and other types of opioid analgesics, and the lack of long-term trials is due to regulatory and ethical issues. Although opioids can cause addiction when used for a long time, tramadol has a reasonable safety profile. According to the patient's condition and the clinical judgment of the medical professional, tramadol can be prescribed for patients, but the consequences of its use must be considered and a personalized treatment algorithm should be selected if the benefits outweigh the risks of the drug.","PeriodicalId":16645,"journal":{"name":"Journal of Pain & Palliative Care Pharmacotherapy","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142502372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction. 更正。

IF 0.9

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2024-10-21 DOI: 10.1080/15360288.2024.2419784

引用次数: 0

Changes in Pain and Mental Health Symptoms Associated with Prescribed Medicinal Cannabis Use: A One-Year Longitudinal Study. 与处方药用大麻有关的疼痛和心理健康症状的变化：为期一年的纵向研究

IF 0.9

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2024-10-21 DOI: 10.1080/15360288.2024.2414898

Andreas Halman, Richard Chenhall, Daniel Perkins

{"title":"Changes in Pain and Mental Health Symptoms Associated with Prescribed Medicinal Cannabis Use: A One-Year Longitudinal Study.","authors":"Andreas Halman, Richard Chenhall, Daniel Perkins","doi":"10.1080/15360288.2024.2414898","DOIUrl":"https://doi.org/10.1080/15360288.2024.2414898","url":null,"abstract":"Chronic pain and mental health issues like depression and anxiety significantly contribute to disease burden in Western countries. While cannabinoids are suggested to have analgesic, anxiolytic and antidepressant properties, evidence, especially for long-term use, is inconclusive. This 12-month observational study evaluated the effects of prescribed medicinal cannabis for 96 patients suffering from pain, as well as sleep disturbances, depression and anxiety. Treatment outcomes for pain, depression, anxiety and sleep problems were assessed at 3, 6, and 12 months using validated instruments. Significant reductions were observed in pain scores and the interference of pain on daily functions, alongside improvements in mental health and sleep. Many patients reported notable improvements in pain severity and reduced use of pain medications in the first 6 months, with a decline at 12 months. Additionally, sustained improvements in depression, anxiety, stress and sleep were observed, with about half reporting substantial improvement. Adverse effects were common but mostly mild or moderate, most commonly dry mouth and sleepiness. These results show that prescribed medicinal cannabis treatment is associated with improvements in chronic pain and mental health symptoms, such as depression, anxiety and stress. However, findings also suggest reduced effectiveness with longer-term use, emphasizing the need for additional research.","PeriodicalId":16645,"journal":{"name":"Journal of Pain & Palliative Care Pharmacotherapy","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142468186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of Cannabis-Based Medicinal Product Formulations for Fibromyalgia: A Cohort Study. 比较治疗纤维肌痛的大麻药用产品配方：队列研究。

IF 0.9

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2024-10-17 DOI: 10.1080/15360288.2024.2414073

Surya Sridharan, Simon Erridge, Carl Holvey, Ross Coomber, Wendy Holden, James J Rucker, Michael Platt, Mikael H Sodergren

{"title":"Comparison of Cannabis-Based Medicinal Product Formulations for Fibromyalgia: A Cohort Study.","authors":"Surya Sridharan, Simon Erridge, Carl Holvey, Ross Coomber, Wendy Holden, James J Rucker, Michael Platt, Mikael H Sodergren","doi":"10.1080/15360288.2024.2414073","DOIUrl":"https://doi.org/10.1080/15360288.2024.2414073","url":null,"abstract":"This cohort study aims to assess the outcomes of fibromyalgia patients enrolled in the UK Medical Cannabis Registry prescribed a homogenous selection of cannabis-based medicinal products (CBMPs). A cohort study of fibromyalgia patients treated with oils (Adven®, Curaleaf International, UK), dried flower (Adven®, Curaleaf International, UK) or both CBMPs was performed. Primary outcomes were changes from baseline at 1, 3, 6 and 12 months in validated patient-reported outcome measures. Secondary outcomes included descriptive analysis of adverse events. One hundred and forty-eight participants were treated with oils (n = 77; 52.03%), dried flower (n = 14; 9.46%) or both (n = 57; 38.51%). Improvements in the generalized anxiety disorder-7 questionnaire, single-item sleep quality scale, fibromyalgia symptom severity score and EQ-5D-5L Index values were observed at each follow up period compared to baseline (p < 0.050). Thirty-six (24.32%) patients experienced 648 adverse events. Improvements were observed across all primary outcomes with no differences observed across different formulations of CBMPs. Adverse events were reported by one-quarter of participants and were more likely to reported by cannabis naïve patients. This present work through focusing on a homogeneous group of CBMPs can help inform randomized controlled trials after observing signals of improvement associated with a specific cultivar of CBMPs.","PeriodicalId":16645,"journal":{"name":"Journal of Pain & Palliative Care Pharmacotherapy","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142468187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Music for Healing: A Careful Application of Music Therapy for the Sick. 音乐治病：为病人精心应用音乐疗法。

IF 0.9

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2024-10-15 DOI: 10.1080/15360288.2024.2389866

Dalmacito A Cordero

引用次数: 0

Caring is Healing: Finding Life Amid Pain and Suffering. 关怀即治愈：在痛苦中寻找生命。

IF 0.9

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2024-10-15 DOI: 10.1080/15360288.2024.2346389

Dalmacito A Cordero

引用次数: 0

Increasing Access to Naloxone in Veterans Receiving Opioids Through Community Care. 增加通过社区护理接受阿片类药物的退伍军人获得纳洛酮的机会。

IF 0.9

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2024-10-10 DOI: 10.1080/15360288.2024.2404590

Kaylee Nichols, Brittany Faley, Lauren Gonser

{"title":"Increasing Access to Naloxone in Veterans Receiving Opioids Through Community Care.","authors":"Kaylee Nichols, Brittany Faley, Lauren Gonser","doi":"10.1080/15360288.2024.2404590","DOIUrl":"https://doi.org/10.1080/15360288.2024.2404590","url":null,"abstract":"The United States is battling an opioid overdose epidemic, and Veterans are at almost double the risk compared to the general population. Veterans Health Administration (VHA) recognizes the critical role naloxone plays as a risk mitigation strategy in opioid prescribing; however, there was not a standardized process within the Kansas City VA Medical Center's (KCVAMC) community care program. This quality improvement project included Veterans that received opioids through community care from 2022 to 2023. The Stratification Tool for Opioid Risk Mitigation and chart review were used along with descriptive statistics. Results found 11% (22 of 206) of Veterans were dispensed naloxone within one year prior to receiving their opioid prescription. This data indicated the importance of expanding access to naloxone in Veterans receiving opioids from community care providers. As a result of this data, the KCVAMC implemented an outpatient pharmacy protocol to dispense naloxone to appropriate Veterans that receive an opioid through the community care program. The protocol was initiated on March 29, 2023. From the end of March through 2023, naloxone dispensing for these Veterans increased from 11% to 67%.","PeriodicalId":16645,"journal":{"name":"Journal of Pain & Palliative Care Pharmacotherapy","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142468189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Topical Formulation of Tramadol 5% in the Management of Osteoarthritis of the Knee: A Double-Blind, Randomized, Prospective, Placebo-Controlled Clinical Trial. 5%曲马多局部制剂用于治疗膝关节骨性关节炎：一项双盲、随机、前瞻性、安慰剂对照临床试验。

IF 0.9

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2024-10-10 DOI: 10.1080/15360288.2024.2384968

Shahram Ala, Parisa Pakzadeh, Mahila Monajati, Reza Enayatifard, Afshin Shiva, Adeleh Sahebnasagh

{"title":"Topical Formulation of Tramadol 5% in the Management of Osteoarthritis of the Knee: A Double-Blind, Randomized, Prospective, Placebo-Controlled Clinical Trial.","authors":"Shahram Ala, Parisa Pakzadeh, Mahila Monajati, Reza Enayatifard, Afshin Shiva, Adeleh Sahebnasagh","doi":"10.1080/15360288.2024.2384968","DOIUrl":"https://doi.org/10.1080/15360288.2024.2384968","url":null,"abstract":"The goal of the present study was to evaluate the efficacy of topical tramadol in the management of knee osteoarthritis pain. Sixty patients with moderate to severe pain of knee osteoarthritis were enrolled. Patients were randomized to receive tramadol 5% or placebo along with oral diclofenac 100 mg/day. They were instructed to apply the ointment every 12 h on the knee for three weeks. To control breakthrough pain, the patients were allowed to take acetaminophen up to 650 mg per day. The measured variables were Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and Visual Analog Scale (VAS). Sixty patients completed the study. At the end of follow-up period, VAS decreased by 21% (from 7.2 ± 2.1 to 5.7 ± 2.4, p-value < 0.05) and WOMAC score decreased by 23% (from 49.6 ± 17.4 to 38.4 ± 18.1, p-value < 0.05) in intervention group. Topical tramadol was significantly effective in reducing the intensity of pain and osteoarthritis symptoms in comparison to placebo considering VAS (5.7 ± 2.4 vs. 8.0 ± 2.9, p-value = 0.001) and WOMAC score (38.4 ± 18.1 vs. 46.0 ± 18.6, p-value = 0.007). Topical tramadol 5% appears to be effective in moderate to severe knee osteoarthritis pain.","PeriodicalId":16645,"journal":{"name":"Journal of Pain & Palliative Care Pharmacotherapy","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142468191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An in-Depth Exploration of Consumer and Consumer Representative Views on Chronic Pain Management in Australia: A Key Informant Interview Study. 深入探讨澳大利亚消费者和消费者代表对慢性疼痛管理的看法：关键知情人访谈研究》。

IF 0.9

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2024-10-01 DOI: 10.1080/15360288.2024.2407461

Ingrid Bindicsova, Leanne M Hides, Melissa A Day

{"title":"An in-Depth Exploration of Consumer and Consumer Representative Views on Chronic Pain Management in Australia: A Key Informant Interview Study.","authors":"Ingrid Bindicsova, Leanne M Hides, Melissa A Day","doi":"10.1080/15360288.2024.2407461","DOIUrl":"https://doi.org/10.1080/15360288.2024.2407461","url":null,"abstract":"Chronic pain affects millions of Australians. Despite guidelines recommending non-pharmacological approaches as the first line treatment, opioid medications remain among the most common treatments. This study interviewed consumers and consumer representatives (i.e., representatives of peak pain advocacy organizations in Australia) to gain first-hand perspectives on chronic pain treatment in Australia. Individual semi-structured Key Informant Interviews (KIIs) with three consumers and three representatives were undertaken. Interviews were transcribed, and thematic analysis applied. Results showed that consumers and consumer representatives identified critical treatment access barriers. Another shared theme related to overarching principles of care, with sub-themes pertaining to the need for an interdisciplinary approach and pain education. A further shared theme focused on typical medical interventions, with one shared subtheme regarding the benefits and drawbacks of pain medications. Both groups highlighted the importance of a biopsychosocial approach with consideration of mental health, particularly related to perceived stigma and comorbidities. These findings highlight that chronic pain remains both undertreated and inadequately treated in Australia. There is a critical need to use novel approaches to overcome access barriers and stigma, and to advance precision medicine to match patients to the treatment most likely to be of benefit as early as possible in their journey.","PeriodicalId":16645,"journal":{"name":"Journal of Pain & Palliative Care Pharmacotherapy","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142365569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0